Ipilimumab-Induced Neutropenia in Melanoma

Makiko Ban-Hoefen MD; Richard Burack MD; Lynn Sievert NP; Deepak Sahasrabudhe MD

doi:10.1177/2324709616661835

Journal of Investigative Medicine High Impact Case Reports (Aug 2016)

Ipilimumab-Induced Neutropenia in Melanoma

Makiko Ban-Hoefen MD,
Richard Burack MD,
Lynn Sievert NP,
Deepak Sahasrabudhe MD

Affiliations

Makiko Ban-Hoefen MD: University of Rochester Medical Center, Rochester, NY, USA
Richard Burack MD: University of Rochester Medical Center, Rochester, NY, USA
Lynn Sievert NP: University of Rochester Medical Center, Rochester, NY, USA
Deepak Sahasrabudhe MD: University of Rochester Medical Center, Rochester, NY, USA

DOI: https://doi.org/10.1177/2324709616661835
Journal volume & issue: Vol. 4

Abstract

Read online

Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies.

Published in Journal of Investigative Medicine High Impact Case Reports

ISSN: 2324-7096 (Online)
Publisher: SAGE Publishing
Country of publisher: United States
LCC subjects: Medicine: Medicine (General); Medicine: Pathology
Website: https://journals.sagepub.com/home/hic

About the journal